Oligometastatic Disease clinical trials

Explore recruiting oligometastatic disease clinical trials.

Recruiting oligometastatic disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Oligometastatic Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART).

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Basket study for oligo-metastatic breast cancer - ANISE

Netherlands, France, Italy, Spain, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC-2014-HNCG: PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

Italy, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the therapeutic treatment of patients with ER+ and HER2- metastatic breast cancer in relapse after first-line therapy combining hormone therapy

France

Therapeutic use (Phase IV) EU CTIS Study details

Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and taxane-resistant Prostate cancer (ChemSABR Prostate)

Estonia

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high-risk stage II and stage III Colorectal Cancer

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Oligometastatic Disease trials by city

Oligometastatic Disease in Toronto Oligometastatic Disease in Vancouver Oligometastatic Disease in Montreal Oligometastatic Disease in Calgary Oligometastatic Disease in Edmonton Oligometastatic Disease in Ottawa Oligometastatic Disease in Winnipeg Oligometastatic Disease in Quebec City Oligometastatic Disease in Hamilton Oligometastatic Disease in Kitchener Oligometastatic Disease in London Oligometastatic Disease in Halifax Oligometastatic Disease in New York Oligometastatic Disease in Los Angeles Oligometastatic Disease in Chicago Oligometastatic Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease